Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2011  |  Volume : 7  |  Issue : 4  |  Page : 442-447

Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: A phase II-III clinical trial


1 Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Radiation Oncology, Golestan Hospital, Ahwaz University of Medical Sciences, Ahwaz, Iran
3 Department of Radiation Oncology, Hormaozgan University of Medical Sciences, Bandar Abbass, Iran
4 Department of Otolaryngology, Head and Neck Surgery, Khalili Hospital and Cancer Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
5 Department of Radiation Oncology, Namazi Hospital and Cancer Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence Address:
Mohammad Mohammadianpanah
Department of Radiation Oncology, Cancer Research Center, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz 71936-11351
Iran
Login to access the Email id

Source of Support: Shiraz University of Medical Sciences as research number project 2664, Conflict of Interest: The authors disclose any commercial or other associations that might pose a confl ict of interest in connection with submitted manuscript.


DOI: 10.4103/0973-1482.92013

Rights and Permissions

Background: This is the first study that aimed to determine the efficacy and safety of concurrent chemoradiation with weekly cisplatin ± celecoxib 100 mg twice daily in locally advanced undifferentiated nasopharyngeal carcinoma. Materials and Methods: Eligible patients had newly diagnosed locally advanced (T3-T4, and/or N2-N3, M0) undifferentiated nasopharyngeal carcinoma, no prior therapy, Karnofsky performance status ≥ 70, and normal organ function. The patients were assigned to receive 7 weeks concurrent chemoradiation (70 Gy) with weekly cisplatin 30 mg/m 2 with either celecoxib 100 mg twice daily, (study group, n = 26) or placebo (control group, n = 27) followed by adjuvant combined chemotherapy with cisplatin 70 mg/m 2 on day 1 plus 5-fluorouracil 750 mg/m 2 /d with 8-h infusion on days 1-3, 3-weekly for 3 cycles. Results: Overall clinical response rate was 100% in both groups. Complete and partial clinical response rates were 64% and 36% in the study group and 44% and 56% in the control group, respectively (P > 0.25). The addition of celecoxib to concurrent chemoradiation was associated with improved 2-year locoregional control rate from 84% to 100% (P = 0.039). Conclusions: The addition of celecoxib 100 mg twice daily to concurrent chemoradiation improved 2-year locoregional control rate.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3538    
    Printed143    
    Emailed3    
    PDF Downloaded399    
    Comments [Add]    
    Cited by others 5    

Recommend this journal